National Bank of Canada FI Sells 5,244 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• National Bank of Canada FI decreased its stake in Regeneron Pharmaceuticals by 5.1%, owning 97,984 shares valued at approximately $62.14 million as of the end of the first quarter.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share, surpassing estimates by $4.46, and recorded a revenue of $3.67 billion for the quarter.
• The company announced a quarterly dividend of $0.88 per share, with a payout ratio of 8.87% and a dividend yield of 0.6%.

National Bank of Canada FI cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 97,984 shares of the biopharmaceutical company's stock after selling 5,244 shares during the period. National Bank of Canada FI owned 0.09% of Regeneron Pharmaceuticals worth $62,142,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Morgan Stanley reiterated an "overweight" rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Bank of America lowered their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Finally, Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $3.20 during mid-day trading on Friday, hitting $563.00. 1,024,297 shares of the stock traded hands, compared to its average volume of 978,475. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a market cap of $59.67 billion, a PE ratio of 14.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The firm has a 50 day simple moving average of $536.80 and a two-hundred day simple moving average of $598.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $11.56 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.